Company-wide revenue
Reported revenue in 2021 ¥12.58B Reported revenue in 2025 ¥13.17B
- growth amount
- +¥597.86M
- growth annualized
- +1.2%
- growth total
- +4.8%
Japanese company profile · 2342
TRANS GENIC GROUP INC.
In its FY2025 public filing, TRANS GENIC GROUP INC. reports Drug Discovery Support Business, Investment and consulting business. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: 株式会社トランスジェニックグループ
English company name recorded in Japan's EDINET filer data. English company name source
Reported company-wide figures
What does this company do?
What does this company do?
TRANS GENIC GROUP INC.'s largest reported business by revenue in FY2025 was Investment and consulting business.
The business with the highest reported segment profit in FY2025 was Investment and consulting business.
FY2025 · fiscal year ended March 2026 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Sales | Revenue share | Operating profit |
|---|---|---|---|
| Investment and consulting business | ¥10.92B ↗ | 82.9% | ¥479.52M ↗ |
| Drug Discovery Support Business | ¥2.26B ↗ | 17.1% | −¥164.12M ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Drug Discovery Support Business
- 創薬支援事業
- Investment and consulting business
- 投資・コンサルティング事業
- Business label unavailable in English
- Ｅコマース
- Other
- その他
- Business label unavailable in English
- ＴＧＢＳ事業
- Sales
- 売上高
- Operating profit
- 営業利益
Original Japanese label
- Drug Discovery Support Business
- 創薬支援事業
- Investment and consulting business
- 投資・コンサルティング事業
- Business label unavailable in English
- Ｅコマース
- Other
- その他
- Business label unavailable in English
- ＴＧＢＳ事業
- Sales
- 売上高
- Operating profit
- 営業利益
What is growing?
What is growing?
Business revenue growth
Drug Discovery Support Business
Reported revenue in 2021 ¥4.77B Reported revenue in 2025 ¥2.26B
- growth amount
- −¥2.51B
- growth annualized
- -17.0%
- growth total
- -52.6%
View original filing
Investment and consulting business
Reported profit margin in 2022 +1.8%
Reported profit margin in 2025 +4.4%
- growth margin points
- +2.6
View original filing
This describes a reported period; it is not a forecast.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2025 · fiscal year ended March 2026
The source document may be in Japanese.
Filing ID: S100YCRI
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.